regn

Welcome to the 'regn' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'regn'.

Are you an expert about 'regn'? Do you want to be the Technorati authority on 'regn'? You can write a description that will appear right here: Join Blogcritics!

Latest blogosphere posts tagged “regn”

 

• A Growth Investor Who Smartly Balances Blue Chips And Biotech

  
  — Authority:
  This is one of a series of blog posts from the Morningstar Investment Conference in Chicago.
  5 days ago

• Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Does This Pipeline Promise Tomorrow’s Blockbuster Sales?

  
  — Authority:
  Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE: MRK ) is no exception. Merck & Co., Inc. (NYSE:MRK)’s one of the industry’s biggest giants, but the loss of patent protection on former top blockbuster drug Singulair and ...
  6 days ago

• Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

  
  — Authority:
  Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB ), saw the most significant rise in short interest between the May 15 and May 31 settlement dates.
  6 days ago

• Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 08:40 AM

  
  — Authority:
  Regeneron Pharmaceuticals, Inc. ( REGN ) June 11, 2013 11:40 am ET Executives Michael Aberman - Vice President of Strategy & Investor Relations Analysts Terence C. Flynn - Goldman Sachs Group Inc., Research Division Presentation Terence C. Flynn - Goldman Sachs Group Inc., Research ...
  1 week ago

• Opko: More Hidden Value In Partnerships, Equity Investments

  
  — Authority:
  By Brian L. Wilson : Recent coverage provided for Opko (NYSE: OPK ) included a simple financial model that supported a surprisingly high (~$1 B) valuation for a Phase III pipeline product hGH-CTP (a modified version of human growth hormone) that was added to the companys pipeline after the acquisition of PROLOR ...
  1 week ago

• 5 Stocks To Watch Closely This Week

  
  — Authority:
  By Bill Maurer : Last week was full of excitement, as the May jobs report sparked a ton of debate over whether the Federal Reserve would start tapering some of its QE program. We also are heading further into the summer, where the number of market participants will decrease as vacations are taken. This week will be ...
  1 week ago

• TheStreetMONSTER Conference Roundup

  
  TheStreet.com — Authority: 544
  NEW YORK (TheStreet) -- Tech, housing, market volatility and quantitative easing were high on the agenda at TheStreetMONSTER investment conference last weekend. On Saturday Jim Cramer discussed the Federal Reserve and quantitative easing during his keynote, and also described his appetite for "retro tech" stocks ...
  1 week ago

• Positive Data on Bayer/REGN’s Eye Drug – Analyst Blog

  
  — Authority:
  Bayer announced positive top-line results from the phase III MYRROR study on VEGF Trap-Eye.
  1 week ago

• Cramer: The Market Welcomes the Jobs Number

  
  TheStreet.com — Authority: 544
  Editors Note: This article was originally published at 10:41 a.m. EDT on Real Money on June 7. To see Jim Cramers latest commentary as its published, sign up for a free trial of Real Money. NEW YORK (Real Money) -- Right back to the generals. Right back to biotech -- Gilead, Celgene, Biogen Idec and Regeneron. Right ...
  1 week ago

• Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs

  
  — Authority:
  The U.S. stock market surged on Thursday after an afternoon rally lifted the major averages out of negative territory. Stocks closed near their best levels of the session, with the Dow adding around 80 points. Around mid-day, the market appeared to be in danger of adding to its recent losses, and a washout was not ...
  1 week ago

• OPKO Looks Lucrative As Acquired HGH-CTP Moves Into Phase III Trials

  
  — Authority:
  By Brian L. Wilson : OPKO Health (NASDAQ: OPK ) has been seeing a steady rise in short interest throughout the last few months - with the last measurement by NASDAQ coming in at 30.16 M shares on May 15th 2013 as speculators begin to question the premium that the market is placing on the company due to the ...
  1 week ago

• Mad Money Lightning Round: Amgens Not a Fave

  
  TheStreet.com — Authority: 544
  Search Jim Cramers "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.NEW YORK (TheStreet) -- Heres what Jim Cramer had to say about some of the stocks callers offered up during the "Mad Money Lightning Round" Wednesday evening: First Interstate Bancshares : "Thats a stock Im looking ...
  1 week ago

• Just A Healthy Pullback? CELG, VIX, DDD, XPY, GS, C, PNC, V, BIIB, CELG, REGN

  
  — Authority:
  Markets struggled to find a direction on Monday.  But, today, dip-buyers shied away from buying.  Stocks were mostly lower.  We locked in gains on our downside trades, including a +204% profit on CELG puts: 12:34 | HappyTrading CELG ($112.50) Sold to Close 06P120 Jun 120 put, at $8.50 +204% 08:09 | ...
  1 week ago

• Cramers Mad Money Recap: Profit While You Can

  
  TheStreet.com — Authority: 544
  Search Jim Cramers "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- What happens what you take housing away from the U.S. economy and dont replace it with something else? You get a market that looks a lot like todays, Jim Cramer said on "Mad Money" Wednesday ...
  1 week ago

• Two More Weekly LCD Sell Signals

  
  — Authority:
  The US stock market failed to continue higher after Mondays rebound, and once again, the overseas markets are putting pressure on US stocks in early trading Wednesday. The Nikkei 225 was hit hard again as it lost 3.26% overnight, and there were greater than 1% losses in several of the Euro markets.
  1 week ago

• Aegerion Pharmaceuticals, Inc. (AEGR): A $90 Price Target for This Biotech! How’s It Figured?

  
  — Authority:
  Aegerion Pharmaceuticals, Inc. (NASDAQ : AEGR ) is currently trading higher by 13% after having its price target raised to $90 by Canaccord – which is now the highest target on the stock. The stock is trading at $68.50 after a one-year 380% gain due to the recent FDA approval of its drug Juxtapid. However, I ...
  2 weeks ago

• Regenerons Blockbuster Drug Eylea And Its Potential Competitors

  
  — Authority:
  By Peter Geschek : Eyleas success Few drugs have ever reached blockbuster status as quickly as Regenerons ( REGN ) eye drug Eylea. In 2012, the company raised its sales estimate for the year four times and in the first quarter of 2013 the drug had sales of $314 million in the U.S. Eylea, which treats ...
  2 weeks ago

• What Is Your Exit Strategy?

  
  — Authority:
  By Bill Gunderson : Building a portfolio in this bull market is kind of like coaching LeBron James: All you have to do is stand up every five minutes and yell "Give LeBron the ball." Pretty soon everyone will think you are a great coach. Maybe its not quite that easy. Coaching or investing. But this market ...
  2 weeks ago

• 2 Potentially Explosive Small Cap Stocks For 2013

  
  — Authority:
  By Kelly Berman : Two small cap companies that are driven by very different forces are well positioned to enjoy large percentage gains this year. The first company develops repurposed drugs that have already been approved for safety by the FDA but are now being developed for different illnesses addressing very large ...
  2 weeks ago

• Regeneron Pharmaceuticals, Inc. Presents at 38th Annual Deutsche Bank Health Care Conference, May-29-2013 08:40 AM

  
  — Authority:
  Regeneron Pharmaceuticals, Inc. ( REGN ) May 29, 2013 8:40 am ET Executives Leonard S. Schleifer - Co-Founder, Chief Executive Officer, President, Executive Director and Ex Officio Member of Technology Committee Michael Aberman - Vice President of Strategy & Investor Relations Analysts Robyn ...
  2 weeks ago

Comments about regn